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Human papillomaviruses (HPVs) have been reported to infect epithelial trophoblastic
cells of the placenta, induce cell death and even cause placental malfunction associated
with spontaneous preterm delivery. To date, no study has been conducted to determine
the role of HIV on HPV genotype distribution and pathogenesis in the placental
compartment. This is despite the evidence that the human immunodeficiency virus (HIV)
can decrease the cellular immune response and increase the incidence of malignant
cancers in HPV patients. Therefore, in this study, we analyzed 200 genomic DNA
(gDNA) samples extracted from paraffin embedded placental tissues of HIV positive and
HIV negative Zambian women. The gDNA was PCR amplified using GP5+/GP6+ and
CPI/CPII primers targeted to the L1 and E1regions of the HPV genome, respectively. We
found the overall prevalence of HPV to be 85.0%. The prevalence of HPV in the HIV+
tissues was 84(80.8%), while that of the HIV- tissues was 86(89.6%). This difference in
HPV prevalence between the HIV+ and HIV- placental tissues was not significant
(p>0.05; p=0.112). Direct sequencing of the PCR products revealed 3 HPV genotypes
namely: HPV6, 16 and 90.We observed a significant difference (p<0.05; p=0.0241) in the
high risk (HR) HPV16 incidence between the HIV+ and HIV- tissue with an odds ratio of
2.1. Because p16 is a surrogate marker for HR-HPV infection, we analyzed the placental
tissue sections by p16 immunohistochemistry (IHC). The relative p16 signal per tissue
area was significantly different (p<0.05; p=0.0142) between the HIV+/HPV16+ and

HIV-/HPV16+ groups. To confirm our L1 PCR findings, we also performed HPV16 L1
IHC and found that the relative L1signal per tissue area was significantly different
(p<0.05; p=0.0132) between the HIV+/HPV16+ and HIV-/HPV16+ groups.
To the best of our knowledge, we are the first group to study HPV in the context of HIV
within the placental compartment.
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LITERATURE REVIEW
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Biology of Human Papillomaviruses
Human papillomaviruses (HPVs) are small, non-enveloped, double-stranded DNA
(dsDNA) viruses (60) that infect squamous epithelial cells (10) and are responsible for
benign warts of the hands, genitals and the larynx (25). To date, as many as 120 different
types of HPVs have been identified, two-thirds of which infect cutaneous membranes and
one-third of which infects mucosal membranes. Based on their ability to cause malignant
carcinomas, the HPVs that target the mucosa can be categorized into the: high-risk type
(HPV type 16, 18, 31) and the low-risk (HPV type 6, 11) type (27). The high-risk HPVs
cause intraepithelial neoplastic lesions which can progress to cervical cancer, whereas the
low-rick HPVs are responsible for genital warts (Condyloma acuminata) and express a
rarity for progression to cancer (10).

Figure 1.1 Organization of the HPV genome.
The HPV16 genome has 8 open reading frames (ORFs). Before productive replication occurs, the
early proteins namely E1, E2, E6 and E7 are expressed. Expression of the late proteins (L1 and L2,
including E1ᴧ E4 and E5) occurs in the more terminally differentiated suprabasal cells.
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The organization of the genes is the same in all human papillomaviruses (Figure 1.1). The
HPV genome is approximately 8000 base pairs (bps) long and is composed of an early
region in which non-structural genes (E1, E2, E4 and E5) are encoded; the late region
which codes for structural genes (L1 and L2) and contains the long control region [LCR]
(27). Each of the viral proteins plays a specific role; for example, E1 acts as a DNA
helicase/ATPase (25) and in concert with E2, a transcriptional transactivator, induce
viral DNA replication. Regulation of the cell cycle control and maintenance of the HPV
viral genome is mediated by the E6 and E7 oncoproteins (19, 27). The E6 protein targets
the tumor suppressor p53 for proteasomal degradation via the E3 ubiquitin ligase (E6AP) complex (54, 73). Additionally, E6 activates the transcription of human telomerase
reverse transcriptase (hTERT) which is a telomerase catalytic subunit (29, 73). The E7
oncoprotein binds and inactivates the retinoblastoma (Rb) protein, which acts as a brake
in the cell cycle. The functional inactivation of Rb therefore prevents Rb from binding to
the E2F transcription factors and consequently allows cells with inactivated Rb to
proliferate uncontrollably (15, 37, 73). The biological role of the E4 protein in human
papillomavirus infections has long been reported to be vague; however, recent studies
have shown that the E4 N-terminal domain of both HPV16 and 18 enables the E4 protein
to interact with cytokeratin. The C-terminal domain, however, allows E4 to induce
cytoplasmic aggregate formation and to disintegrate the network structure of the
cytokeratin intermediate filament (39). The E5 protein is a transmembrane protein that in
the bovine papillomavirus (BPv) activates the platelet-derived growth factor β (PDGF-β)
receptor tyrosine kinase by a mechanism that does not require a ligand. The BPV E5
protein induces receptor dimerization activation and, trans-phosphorylation and receptor-
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associated recruitment of signaling proteins by forming a stable complex with the
receptor. It is speculated that the E5 human papillomavirus protein could also affect the
activity of PDGF-β and its signaling pathways in a similar fashion (12). The L1 protein
is the major capsid protein which by itself can spontaneously assemble into virus-like
particles (VLPs) in many expression systems of eukaryotes (17, 28). The role of the L2
protein is to bind DNA and mediate encapsidation (17, 82).
The HPV Life Cycle
The human papillomavirus life cycle is driven by the differentiation program of the
infected keratinocytes. Infection of the basal layer cells with HPV initially occurs when
there are minor abrasions or microtrauma in the epithelia (4). There is evidence to show
that HPV entry into host cells occurs when virus like particles (VLPs) bind with
specificity to the alpha 6 (α6) integrin subunit. The formed VLP- α6 complex containing
either β1 or β4 integrin then serves as a receptor for the binding of the papillomavirus and
therefore facilitates its entry into epithelial cells (17). The HPV life cycle is characterized
by a genome maintenance phase, a proliferative phase, a genome amplification phase and
a virus synthesis phase (14) in that order. The E1 and E2 proteins are thought to be
expressed first, following infection and uncoating of the virus, in order to induce DNA
replication (25) and establish a stable episomal viral DNA state (14, 74). The episomal
viral genomes are tethered to the cellular factors via the E2 protein. This interaction
results in the correct segregation of HPV genomes into daughter cells (36). During this
phase, viral DNA replication occurs independently of the cell cycle and the viral copy
number is amplified between 50 and 100 copies per cell. Furthermore, the expression of
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high-risk HPV E6 and E7 oncogenes is regulated tightly and their respective transcripts
cannot be detected in the proliferating epithelial compartment (61).

Figure 1.2 The human papillomavirus (HPV) life cycle.
Infection with HPV occurs when there is a micro-wound in the skin which acts as a conduit for the
virus to the basal cells. The virus replicates episomally in basal cells at low copy number. The HPV
viral life cycle is controlled by the host cell differentiation program. In the more terminally
differentiated cells of the upper epithelial layers, productive life cycle occurs and this followed by the
release of virion particles in the cornified keratinocytes

Genome maintenance is followed by a proliferative phase during which the number of
basal cells harboring extrachromosomal viral DNA increases (14) to several thousands of
copies per cell. This occurs when infected basal cells egress into the stratum spinosum,
which is under active differentiation, and is accompanied by increased viral gene
expression and viral DNA replication? Furthermore, the early genes (E6 and E7) are
expressed abundantly and this is accompanied by the late gene expression from the late
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promoter region (8, 61). In infections with the high-risk HPVs, E6 and E7 are expressed
as oncogenes (14, 57). On the other hand, these proteins play no detectable oncogenic
role in infections associated with the low-risk HPVs (34). The binding of the high-risk E6
transforming protein to the p53 tumor suppressor protein in concert with the E6AP
cellular ubiquitin ligase (34, 55, 70) results in the targeting of p53 for proteasome
degradation (61). The binding of the high-risk E7 oncogene to the unphosphorylated
retinoblastoma tumor suppressor protein (Rb), phosphorylates the latter and releases the
E2F transcription factor from the E2F-Rb complex. This allows E2F to bind cellular
DNA and upregulate the expression of cell proliferation genes (69). The complementary
role of E6 to E7 is thought to thwart apoptosis following the entry of the cell cycle into
the S-phase (14).
During the late phase of the HPV lifecycle, the L1 and L2 proteins are assembled into
icosahedral capsids. Virion assembly is accompanied by the release of mature viruses
from the stratum corneum (34).
Biology of HPV and HIV Infection
Human papillomavirus (HPV) infections have been reported to be prevalent in human
immunodeficiency virus (HIV) positive individuals (13). There is evidence to show that
HIV-positive women have a high prevalence of HPV infections in the cervix (23, 42, 63)
and a study conducted by Ahdieh and colleagues showed that HIV-positive women were
1.8, 2.1 and 2.7 times more likely to harbor high-, intermediate-, and low-risk HPV
infections, respectively, than HIV-negative women. The persistence of HPV lesions was
approximately twice greater in women with a CD4 cell count less than 200 cells/µl
compared with greater than 500 cells/µl (1).
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The number of sexual partners is one of the key risk factors for HPV acquisition. This is
in agreement with findings that have suggested that individuals infected with HIV tend to
have a higher prevalence of anogenital infections, (9, 42) with a lower CD4+ count being
one of the most consistent risk factors for anogenital intraepithelial neoplasia. Thus,
immune suppression due to HIV infection may play an important role in the development
of high-grade intraepithelial neoplasia and eventual progression to cancer (42). The
importance of cell-mediated immunity in the control of HPV infection has been
evidenced by studies that have documented an increased prevalence and progression of
HPV infections in the immunosuppressed (56, 59). Multiple recurrences of cervical HPV
infections occur in HIV infected patients (20, 59). HIV may attenuate the systemic
immune response against HPV via its effect on CD4+ cells and regulation of immune
responses to different types of antigens. A low number of circulating HPV specific
memory cells is thought to make the HPV-specific immunity vulnerable to the effects of
HIV (42).
Biology of the Placenta
The placenta is an organ assembled from maternal and fetal cells and is involved in
nourishing and protecting the fetus (81). Placentation is initially characterized by
implantation of the blastocyst directly underneath the uterine epithelium followed by
differentiation into embryonic and extra-embryonic tissues (5).
In humans, anchorage of the placenta in the uterine implantation site, known as the
decidua, is mediated by invasive extravillous trophoblasts (EVT) which are involved in
invading and restructuring maternal arteries to ensure that maternal blood flows into the
intervillous space, bathing the fetally derived villous trees (81). The tertiary chorionic
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villi consist of an outer layer of trophoblast covering mesoderm and blood vessels which
connect proximally to the umbilical arteries and therefore separating maternal and fetal
blood in a haemochorial pattern. The coordinated development of mature villous trees is
vital for the growth and health of the fetus during the third-trimester of pregnancy. The
villous trophoblast is a heterogeneous population of cells that make up the outer layer of
the villi whose original columns of the cytotrophoblast are dispersed initially into a
monolayer of cells that reside on a basal lamina. Finally, the proliferating stem cells give
rise to the syncytiotrophoblast (5, 26) which plays an important role by providing
resistance during pregnancy to a wide variety of pathogens, including cytomegalovirus
[CMV] (18, 81), Listeria monocytogens (47, 81) and Toxoplasma gondii (48, 81). The
blood-bathed surface of the syncytium cannot be breached by gastrointestinal pathogens
such as Listeria monocytogens because it is void of E-cadherin, a host cell surface
receptor that interacts with the virulent determinant internalin A protein (30, 81).
Therefore, the lack of expression of E-cadherin and the absence of intercellular junctions
on the syncytium is thought to be the main defensive mechanism by which adherence and
internalization of Listeria monocytogens is thwarted (30, 47, 81). Additionally, invasion
of host cells by Listeria monocytogens has been linked to abundant fused mitochondria
(62, 81) which is unusually fragmented in the syncytium (68, 81). Thus, multiple unique
biological properties make the syncytium an effective barrier to infection and the
presence of a syncytium in placentas could be an evolutionary protective mechanism
against blood-borne microbes and the transmigration of maternal leukocytes (11, 81).
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Evidence of Placental HPV Infection
The high risk human papillomavirus type 16 has been shown to infect and productively
replicate in 3A trophoblasts in tissue culture (77) and there is evidence to show that
multiple HPV types 11, 18 and 31 can also replicate in these cells in vivo (78). Infection
of embryonic trophoblast cells with HPV16 has been shown to result in spontaneous
abortions (24). This occurs because HPV infection of extravillous trophoblasts induces
cell death and may reduce placental invasion into the uterine wall (21). Prior work by
Chan and colleagues showed that oocytes were capable of absorbing foreign DNA in the
absence of sperm and that the zona pellucida had no barrier effect to the absorption of
small DNA fragments by oocytes (6). This finding was supported by a subsequent study
in which it was shown that mouse embryos at the blastocyst stage could passively and
differentially take up exogenous human papillomavirus (HPV) DNA derived from the
different HPV types 6b/11, 16 and 18 (7).
In vitro studies on mouse blastocysts after 24-hour exposure to HPV16 DNA have shown
that DNA fragmentation occurs. This finding suggests that HPV type 16 may initiate
apoptosis by disrupting DNA in the embryo (3) which might be one of the factors that
lead to spontaneous preterm delivery (24).
Transplacental transmission of human papillomaviruses (HPVs) is well documented, with
type–specific HPV concordance occurring between the mother, the placenta and the
newborn or the mother and cord blood (50). A recent study showed that HPV DNA
could be detected in 5% of neonates born to healthy women and that the HPV DNA could
be associated with detection of HPV in mothers not only in the third, but also the first or
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second trimester of pregnancy. There is a lot of controversy surrounding maternal-to-fetal
transmission of HPV (31). This is because placental contamination with cervical cells
from an infected birth canal cannot be ruled out. However, placental samples obtained
from women undergoing trans-abdominal chorionic villous sampling have revealed the
presence of HPV16 and HPV62 in a couple of placentas (71). Other studies have
confirmed detecting HPV type 18 in both placental tissue samples and the cervix in
pregnant women, with placental HPV infection being unrelated to the mode of child
delivery (66). Further evidence by In Situ Hybridization has shown that HPV DNA can
be localized in placental trophoblasts (52).
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CHAPTER II
INTRODUCTION
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Introduction
Human papillomaviruses are small, non-enveloped double-stranded DNA viruses that
infect squamous epithelial cells via micro-abrasions which may occur on genitalia the
(60). To date, approximately 200 different genotypes of HPVs have been identified (2,
61). Two-thirds of these infect cutaneous membranes and one-third infects mucosal
membranes. Based on their ability to cause malignant carcinomas, the HPVs that target
the mucosa can be categorized into the high-risk (HPV16,18,31) and the low-risk types
(HPV6,11) (27). Infection with the low-risk HPVs usually result in benign epithelial
warts, while infection with the High-risk HPVs leads to anogenital malignancies,
including cervical cancer (58).
It has been shown previously that HPV16 and 31b can infect and replicate in 3A
trophoblasts (33, 76).
Besides mediating nutrient and gas exchange between the fetus and mother, the fetal
trophoblast cells are in direct contact with the maternal tissues and play a crucial role in
placentation (32). Based on this intimate contact and communication between the
maternal and fetal sides of the placenta, it is thought that infection with HPV16 may
result in the death of placental trophoblasts, malfunction in the recognition capability of
endometrial cells or malignancy. These changes may consequently disrupt the integrity of
the trophoblast layer and cause spontaneous abortions or preterm delivery (32, 80).
The Human Immunodeficiency Virus (HIV) has been previously reported to decrease the
cellular mediated immune response (42) and increase the incidence of HPV (56, 59).
However, there is a dearth of information on the role of HIV on HPV genotype
distribution and pathogenesis in the placental compartment. To this end, the present study

13

is aimed at understanding the extent to which HIV infection influences HPV infection
and genotype distribution within the placental compartment. In regard to our main study
objective, we determined the HPV genotypes harbored by placentas from HIV+ and HIVwomen. We also determined the p16 and the HPV16 L1 major capsid protein levels in
placental lesions from HIV-/HPV16+ and HIV+/HPV16+ samples. Finally, we
determined sites of HPV infection by probing for HPV DNA in placental tissues.
Understanding the pathogenesis of HPV infection in the context of HIV infection within
the placental compartment will provide insights into developing methods that can help
prevent co-transmission of the two viruses from the mother to the child. This will be of
particular importance in low income Sub-Saharan countries such as Zambia which are
endemic to both HIV and HPV.
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CHAPTER III
PLACENTAL HPV INFECTION IN HIV NEGATIVE AND HIV POSITIVE
ZAMBIAN WOMEN
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Study Design
This was a Retrospective Cohort study in which the influence of HIV on HPV infection
in the placenta was assessed.

Figure 3.1 Placental HPV Infection Study Design
A cohort of 200 HIV+ and HIV- Paraffin Embedded Placental Tissues (PEPTs) was used
in the study. Initially, genomic DNA was extracted and PCR amplified using GP5+/GP6+
and CPI/II primers. Beta (β)-actin primers were also used as controls. The expected
150bp PCR product was cloned into the pGEM-T Easy Vector System I followed by
direct sequencing. Genotyping was achieved by aligning the sequences and blasting
against the NCBI data base. Histological analysis of HPV16 in the tissues was done using
immunohistochemistry (IHC)
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Study Participants
The study participants were previously recruited at the University Teaching HospitalLusaka, Zambia. Informed consent of the patients was sought before the placental tissue
samples were used in research study.

Sample Collection
A total of 200 Paraffin Embedded Placental Tissues (PEPTs) were obtained from Dr.
Charles Wood’s Laboratory Placental Tissue Bank. These tissues were obtained with
informed consent from HIV negative and HIV positive Zambian women at the time of
delivery. The samples were fixed in formalin and embedded in paraffin prior to being
shipped to Nebraska Center for Virology (NCV) at University of Nebraska-Lincoln
(UNL). To be included in the study, the placental tissue sample of the index patient had
to be either HIV positive or HIV negative.

Genomic DNA Extraction
Genomic DNA was extracted from 200 paraffin embedded placental tissue samples using
the Phenol-Chloroform extraction protocol as described by Pikor et al (43). Each of the
paraffin embedded placental tissues was micro-sectioned and treated with 800 µl of
xylene, to dissolve the paraffin wax from the tissues, followed by rehydration using a
series of 800 µl ethanol (100%, 70% and 50%) washes. Tissue digestion was achieved by
using 20 µl (20 mg/ml) of proteinase K, which was added in the morning and evening
followed by incubation at 56⁰ C in a heating block (Incublock™, Denville Scientific Inc,)
for three consecutive days. This ensured that the tissue dissolved completely. The DNA
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was cleaned up by the phenol-chloroform extraction method after which it was treated
with 100 µg/ml of RNase A to remove any contaminating cellular RNA. Finally, the
purified DNA was eluted in 50 µl nuclease free water and quantified by the Nano Drop
Spectrophotometer (ND-1000).
Beta (β)-actin and HPV Amplification
The DNA extracted from placental tissue samples were amplified using regular PCR.
Two redundant primers, (GP5+:5’-TTT GTT ACT GTG GTA GAT ACT AC-3’ and
GP6+:5’-GAA AAA TAA ATG TAA ATC ATA TTC-3’) that amplify 150 bp of the L1
region (nt 6624-6746) of the HPV genome was used to detect HPV (40) in the samples.
Another pair of redundant primers (CPI: 5’-TTA TCWTAT GCC CAY TGT ACC AT3’-and CPII: 5’-ATG TTA ATW SAG CCW CCA AAA TT-3’) which are targeted to
the E1 region (nt 1777-1964) and amplify 188 bp of the HPV genome was also used to
detect HPV in the samples. We also used β-Actin primers (Forward Primer: 5’-GCC
ATG TAC GTT GCT ATC C-3’ and Reverse Primer: 5’CCG CGC TCG GTG AGG
ATC-3’). The use of these sets of primers on our samples and the simultaneous detection
of HPV with both sets of primers provided a robust set of results for our analysis. The
thermal cycler model, TECHNE, TC-412, was used for amplification. The parameters for
denaturation, hybridization and extension were as follows: 94⁰ C for 1 minute, followed
by 30 cycles of 95 ⁰ C for 30 seconds, 55 ⁰ C for 1 minute, 72 ⁰ C for 10 minutes and final
hold at 4 ⁰ C. The positive control constituted the HPV16 Plasmid DNA (pEF399),
whereas the negative control was nuclease free water. To determine the presence or
absence of HPV fragments and of Beta (β)-actin amplified from the oligonucleotides,
30µl of the PCR product from each sample was pre-mixed with 1.5 µl 6X loading dye
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and separated by gel electrophoresis on 2% (w/v) agarose gel, in 1X TAE buffer. At the
end of electrophoresis, the gel was stained with 0.3% ethidium bromide (0.1 mg/ µl
solution) for 30 minutes and visualization of the DNA fragments was performed under
ultraviolet light.
Cloning of the PCR Products
Following PCR amplification of genomic DNA, the 150 bp amplicon was excised and
purified from the 2% (w/v) agarose gel using the Qiaquik gel extraction kit (Qiagen) after
which 1 µl of the pcr product was cloned into the pGEMT-Easy Vector system I
(Promega Corporation. WI, USA) and incubated at 4 ⁰ C overnight. The clones were then
transformed into DH5-alpha (α) competent cells (100 µl/plate), followed by incubation at
37⁰ C overnight on Luria Broth (LB) plates pretreated with 40µl (20mg/ml) of 5-bromo4-chloro-3-indolyl-be-ta-D-galactopyranoside (XGAL) and 100 µl (20mg/ml) of
isopropyl-beta-D-thiogalactopyranoside (IPTG).

Based on the Blue-white colony

selection principle, two single white colonies from each plate were then isolated, cultured
in 3ml LB containing 5 µl of 50mg/ml Ampicillin and incubated at 37⁰C for 12 hours in a
shaking incubator. The plasmid DNA samples were then purified using the QIAprep Spin
Mini-Prep Kit (Qiagen Inc. CA, USA) after which EcoR I Restriction Digestion of at
least 1.5 µg of Plasmid DNA was performed in a 20 µl reaction volume to ensure that the
plasmids had the correct 150 bp insert.
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Sequencing of the HPV Clones
All the plasmid DNA samples containing the 150 bp insert were analyzed by Direct
Sequencing using the ABI Prism Big Dye Terminator v3.1 Cycle Sequencing. The Direct
Sequencing PCR Master Mix was performed in a 10ul reaction mixture containing 1.0 ul
of 2pmol/ul GP5+ Forward Primer, 1.0 ul of 150ng/ul Plasmid DNA, 4.0ul Big Dye Mix
and 4.0 ul of nuclease free water with the following PCR thermal profile reaction
conditions: Hot start at 95⁰C for 5 m; 35 cycles of 95⁰C for 30s, annealing at 55⁰C for
15s, followed by extension at 60⁰C for 4 m and final hold at 4⁰C. This was followed by
precipitation of the PCR product as recommended by the manufacturer. The HPV
genotypes were determined by comparison with the NCBI GenBank database.
Immunohistochemistry (IHC) Staining
(a) Trophoblast Marker (HSD3B1) Immunohistochemistry
For this purpose, we raised a monoclonal antibody against hydroxyl-delta-5-steroid
dehydrogenase (HSD3B1) as recommended by Mao et al (35). The slides containing the
sectioned tissues were baked for an hour at 60⁰ C in an incubator and allowed to cool for
30 minutes at room temperature before rehydrating with 5 minute incubations in Xylene
1 and 2,

Absolute alcohol 1 and 2, 85% Alcohol and 75% Alcohol. Endogenous

peroxidase in the tissues was blocked for 20 minutes with 2 mL 30% Hydrogen peroxide
per 200 mL methanol, followed by rinsing in distilled water three times for three minutes.
Next, the slides were treated in 0.02% Sodium citrate (v/v) and cooked for 20 minutes at
95⁰ C to unmask the epitopes, after which they were cooled for 20 minutes at room
temperature, while still immersed in the sodium citrate solution. This was followed by
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rinsing in Phosphate Buffered Saline (PBS) for 5 minutes and rimming the tissue sections
with a pap pen, carefully making sure that the slides did not dry. Blocking was achieved
by incubating the slides in 150 µL 10% Normal Goat Serum (10% NGS in PBS) for 30
minutes in a humidity chamber containing a little water. Next, the blocking solution was
flicked off the slides and 150 µL of the Monoclonal anti-HSD3B1 produced in mouse
[SIGMA-ALDRICH] was added at a dilution of 1:2000. The primary antibody was,
however, not added to the negative control slide. This was followed by an hour of
incubation in a humidity chamber. Next, the slides were rinsed in PBS; three changes,
three minutes each followed by addition of three drops of anti-mouse DAKO Envision +
Horseradish Peroxidase (HRP) labeled Polymer (REF: K4001) and incubation in a
humidity chamber for 30 minutes at room temperature. The slides were again rinsed in
PBS; three changes; three minutes each. Using one slide, 200 µL 2, 3Diaminobenzidamine (DAB) solution (1 drop of DAKO DAB+ Chromogen –REF:
K3468 and 1 ml per 1mL of DAKO DAB+ substrate buffer- REF: K3468) was added and
stain development was observed under the microscope, taking note of the time for
optimal intensity. The rest of the slides were then developed using the same time that the
DAB solution on the trial slide took to develop to the desired intensity. The slides were
then washed in 200 mL of distilled water using two changes for five minutes each,
followed by dipping them in undiluted hematoxylin for 20 seconds. The hematoxylin was
washed off by letting the slides sit in running tap water for two minutes and then dipping
them in ammonia water (500 µL ammonia + 1000 mL of water) for 12 seconds, followed
by dehydration sequentially as follows: 70% Alcohol; 85% Alcohol; 100% Alcohol;
100% Alcohol for five minutes each and two changes of Xylene for five minutes each.
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Finally, cytoseal was used to coverslip the slides, leaving them overnight to dry before
microscopic examination the following day.
(b) p16 Immunohistochemistry Staining
The same IHC protocol was used except that 150 µL of the p16 primary antibody
solution (1:20 dilution) was added, followed by 1 hour incubation in a humidity chamber
containing a little water. The primary antibody used was p16 (JC8): sc-56330 purchased
from SANTA CRUZ Biotechnology, Inc. This is a mouse monoclonal antibody raised
against full length recombinant p16 of human origin. The negative control slide was
stained in the absence of the primary antibody whereas the test samples were treated with
both primary and secondary antibodies.
(c) p16 Quantification
For this purpose, two slides of each sample were used. Quantification of the p16 protein
in both HIV positive and HIV negative tissue sections was performed using Image- Pro
Version 9.0. The average p16 expression in each sample was normalized to the tissue
area. We also quantified p16 expression in the HPV negative tissues. Statistical analysis
to compare how the relative p16 expression varied across the groups was performed
using the Kruskal- Wallis of GraphPad Prism 5. Further comparisons to determine
differences, if any, in

the relative p16 signal between the HIV-/HPV16- and

HIV+/HPV16- as well as between the HIV-/HPV16+ and HIV+/HPV16+ groups were
compared using the Mann-Whitney test.
(d) HPV16 L1 Immunohistochemistry Staining
Using the same IHC protocol we used an anti-V5 L1 monoclonal antibody (mAb) to
probe for the HPV16 L1 protein in the placental trophoblasts. The mouse monoclonal
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anti-V5L1 mAb is a type-specific neutralizing antibody which had been previously raised
against human papillomavirus (HPV) type 16 L1 and was able to block more than 75%
infectivity (67). In our study, a 1:250 dilution of the mouse monoclonal anti-L1 gave the
best staining results for the L1 protein.
(e) HPV16 L1 Quantification
For this purpose, two slides of each sample were quantified and averaged. Quantification
of the HPV16 L1 protein levels in both HIV negative and HIV positive tissue sections
was performed using Image- Pro Version 9.0. The average HPV16 L1 protein expression
in each sample was normalized to the tissue area. We also quantified HPV16 L1
expression in the HPV negative tissues to determine the baseline. As in the case of p16
quantification, statistical analysis to compare how the relative HPV16 L1 expression
varied among groups was performed using the Kruskal-Wallis of GraphPad Prism 5.
Further comparisons to determine differences, if any, in the relative HPV16 L1 signal
between the HIV-/HPV16+ and HIV+/HPV16+ groups were compared using the MannWhitney test.
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RESULTS
Patient Samples
Our study samples were composed of paraffin embedded placental tissues which were
obtained from HIV positive and HIV negative women who had been admitted to the
University Teaching Hospital (UTH), Lusaka, Zambia for delivery of their babies. These
samples were then shipped to Nebraska Center for Virology (NCV) and stored in the
Tissue Bank of Dr. Charles Wood, who kindly provided them for our HPV analyses. We
chose to analyze these samples in order to determine if HPV infection was influenced by
HIV. Very little is currently known about HPV infection in the placenta or the effect of
HIV on those infections. Two-hundred samples, (100 HIV negative and 100 HIV
positive) were analyzed.
Detection of HPV in Placental Tissues
HIV and HPV are endemic in Zambia. The prevalence rates for HPV as high as 97.2%
have been previously reported among HIV positive Zambian women (51). Based on
recent studies that suggest that HPV can infect epithelial linings of the placenta (53, 72),
we decided to probe for the presence of HPV DNA in placental tissues of both HIV
positive and HIV negative Zambian women. This goal of this study was to determine the
effect of HIV upon HPV infection and pathogenesis in the placenta. For this purpose, we
used a cohort of 200 placental tissue samples from which we extracted genomic DNA
and PCR amplified HPV DNAs using GP5+/6+ and CPI/II primers. These redundant
primers can amplify up to 40 different types of HPVs. The status of the cellular DNA in
the samples was monitored by β-Actin PCR and any samples that did not test positive for
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β-Actin PCR were excluded from the study. To this end, we excluded 4 samples from the
100 HIV negative samples based on their poor cellular DNA status. To make up for this
decrease in the number of HIV negative samples, we added 4 more samples to the 100
HIV positive samples. Therefore, we finally had 96 HIV negative samples and 104 HIV
positive genomic DNA samples for HPV analysis.
Figure 3.2 shows representative PCR results that were obtained by amplification of the
L1 (nt 6624-6746) and E1 (nt 1777-1964) regions of the HPV genomes using GP5+/6+
and CPI/II primers, respectively. HPV DNAs were detectable in both HIV positive and
HIV negative samples. A plasmid containing the entire HPV16 genome (pEF399) was
used as a positive control.

Figure 3.2 HPV PCR results obtained after amplification. (A) A 150bp PCR product from
the HPV L1 region of HIV negative DNA using GP5+/6+ primers (B) 188bp of the HPV E1
region of HIV negative DNA using CPI/II primers. The cellular DNA status was assessed by
β-Actin polymerase chain reaction. Nuclease free water was used as a negative (-) control,
while pEF399 was used as a positive (+) control in GP5+/6+ PCR amplified samples, whereas
gDNA for extracted from a B cell line was used as a positive control in β-Actin PCR
amplified samples. The test samples were numbered as shown in Figures 3.2 (A) and (B). The
HIV positive DNA samples were also PCR amplified in the same way (Results not shown).
“M” is the marker.
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Determination of HPV Prevalence
After detection of HPV in the DNA samples by PCR, the prevalence rate was determined.
Figure 3.3 shows the prevalence of HPV in the study population. The overall HPV
prevalence rate was 85.0%, with the HIV negative group accounting for 86(43.0%), and
the HIV positive group accounting for 84(42.0%). Statistical analysis showed no
significant difference (Fischer’s Exact test: p>0.5; p=0.112) in the prevalence of HPV
between these two groups.

Figure 3.3 Prevalence of HPV in HIV- and HIV+ placental tissues
The prevalence of HPV in the HIV- placental tissues 86(89.6%) was higher than that of the
HIV+ ones 84(80.8%). Comparison of the prevalence of HPV between the HIV+ and HIVplacental tissues using Fisher’s Exact test showed no significant (ns) difference (p>0.05;
p=0.112).

HPV Genotype Distribution
Having determined the prevalence of HPV in the placental samples (Figure 3.3), we
sought to clone and sequence the PCR products in order to determine their HPV
genotypes.
BLAST analysis of the sequences against the NCBI database revealed three types of
HPVs in our cohort study. These were the Low-Risk (LR) HPV6, the High-Risk (HR)
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HPV16 and the rarely reported HPV90. Eighty six (89.6%) HIV negative samples tested
positive for HPV and 83(96.5%) of these were genotyped whereas the HPV genotype
status of the remaining 3(3.5%) samples could not be determined. The HIV negative
group harbored HPV90 which accounted for 4(5.0%) whereas the LR-HPV6 and HRHPV16 accounted for 57(69.0%), and 22(26.0), respectively.
Of the 84(80.8%) HIV positive samples that tested positive for HPV, 83(98.8%) were
genotyped while the HPV genotype status of 1(1.2%) sample could not be determined.
The HPV positive group had the same HPV90 distribution 4(5.0%) as the HIV negative
group. However, the HPV6 distribution in this group was 44(53%) and that of HPV16
was 35(42%). Comparison of the HPV16 distribution between the HIV+ (42%) and the
HIV- (26%) groups using Fisher’s exact test showed a statistically significant difference
(p<0.05; p=0.0241) with a 2.1 odds ratio. We did not find a significant difference
(p>0.05; p=0.0864) in the distribution of HPV6 between the two groups.
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Figure 3.4 The distribution of HPV in HIV-negative and HIV-positive placental samples.
Three types of HPVs were isolated including the low risk (LR)-HPV6, high-risk (HR)-HPV16 and
the rarely reported HPV90. (A) The pie-chart on the left side shows the distribution of HPV
genotypes in HIV negative placental tissues and; (B) The pie-chart on the right side shows the
distribution of HPV genotypes in HIV positive placental tissues. To determine the HPV
genotypes, the PCR products were cloned into the pGMET-Easy Vector System I followed by
EcoRI restriction digestion. The clones were subjected to Prism ABI Direct sequencing and the
sequences were compared to the NCBI database for genotype identification. There was a
significant difference (p<0.05; p=0.0241) in the distribution of HPV16 between the HIV-/HPV16+
and the HIV+/HPV16+ groups, with an odds ratio of 2.1. There was no significant difference
(p>0.05; p=0.0864) in the distribution of HPV6 between the HIV-/HPV16+ and the
HIV+/HPV16+ groups.

Socio-Demographic Characteristics of Women by HPV Status and Genotype
Distribution

We wanted to know whether the socio-demographic characteristics of women (from
whom the samples had been obtained) were related to the prevalence of particular HPV
genotypes present in placental tissues.
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Table 1 shows the socio-demographic characteristics of the women by HPV status and
genotype distribution and HIV status. The data shows that overall; the most significant
effects were in HIV-dependent effects on HPV genotype distribution. We found a
significant difference (Fischer’s Exact test: p<0.05; p=0.0241) in HPV16 genotype
distribution between the HIV+ and HIV- women. There was no significant difference in
HPV6 (Fischer’s Exact test: P>0.05; p=0.0864) distribution between the two groups.
Furthermore comparison of age, years of education and household size between the HIV
positive and HIV negative women did not reveal any significant difference (Fishers’
Exact test: p>0.05) in HPV genotype distribution.
Table 1: HIV Negative and HIV Positive Women
Table 1 shows the socio-demographic characteristics of HIV negative and HIV positive
women by HPV status and genotype distribution. The HPV status and genotype
distribution were compared with the marital status, age, and years of education. We also
analyzed the effect of household size on HPV status and genotype distribution.
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Comparison of Resident HPV Genotypes in the Vaginal and Placental
Compartments
Table 2 shows a comparison of the HPV genotypes resident in the vaginal and placental
compartments of individual patients. The vaginal HPV study was previously conducted in
our laboratory using lavage samples from same patients by the same PCR and genotyping
methods as used for the present study. Twenty different types of HPVs were recovered
from the vagina whereas only 3 HPV genotypes were recovered from the placenta.

Table 2: HPV Distribution in the Vagina and Placental Compartments

Compartment
Sample
ID

HIV
Status

Vagina

Placenta

79
112
132
919
78
186
1542
1543
107
126
64
81
133
184
984

+
+
+
+
+
+
+

None
None
None
6
None
81/62
None
None
45
None
None
16
51
83
53/6

6
90
None
6
6
6
None
None
6
6
16
None
None
None
None
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Comparison of the vaginal lavage HPV types to those that we discovered in the placental
compartment showed that the HPV genotypes resident in the two compartments were
different, except for sample 919 which had a concordance of HPV6 in both
compartments. We also noted that the vaginal compartment had mixed HPV infections
while the placental compartment had none. Furthermore, we noted that infections were
often exclusive to a single compartment (10/15 samples). The results of the analysis of
HPV genotypes in the vaginal versus the placental compartments suggest that tissue
compartment specific distributions of HPVs exist within individuals.
Trophoblast Marker (HSD3B1) Immunohistochemistry Staining
To identify epithelial syncytiotrophoblast cells, we used antibody to hydroxyl-delta-5steroid

dehydrogenase

(HSD3B1)

which

exclusively

expresses

in

terminally

differentiated layer of trophoblasts cells. This marker has been shown to stain
syncytiotrophoblasts in placental tissues with high specificity and sensitivity (35).
Figure 3.5A is a negative control that was stained in the absence of the primary antibody,
while Figure 3.5B is the positive control tissue stained with the primary antibody. While
no staining was observed in the negative control slide, the Trophoblast marker
specifically stained the syncytiotrophoblastic cells on the outer surface of trophoblasts.
The cytotrophoblastic cells were negative for HSD3B1 staining.
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Figure 3.5 Immunoreactivity of HSD3B1 in fetal placenta. (A) HSD3B1 immunoreactivity in the
presence of secondary antibody without primary antibody. (B) HSD3B1 immunoreactivity was
detected in syncytiotrophoblasts. HSD3B1 was expressed as a brown pigment and
characteristically stained trophoblastic columns. The cytotrophoblastic cells were negative for
HSD3B1 immunoreactivity.

Detection of p16 Protein
The cyclin dependent kinase inhibitor (p16) is a cellular protein whose expression is
elevated in infections with the high risk HPVs, such as HPV16. This occurs because the
high risk HPVE7 oncogene binds the E2F-pRb complex and causes the release of the E2F
transcription factors. This facilitates the binding of E7 to pRb which causes an upregulation of p16. Therefore, p16 is a biomarker for the high risk HPVs (38, 46, 65) and
to this end, we sought to determine the expression of p16 protein in HIV-/HPV16-,
HIV+/HPV16-, HIV-/HPV16+ and HIV+/HPV16+ placental tissues. The expression of
p16 protein was observed in all the four groups of placental tissues (Figure 3.5). The
control conditions without primary p16 antibody showed no background staining of the
placental tissue (Figure 3.5 B).
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The p16 staining was observed both in cytotrophoblastic and syncytiotrophoblastic cells
of the tissues whose genomic DNA had previously tested positive for HPV16 PCR. The
expression of p16 in the HIV+/HPV16+ placental tissue (Figure 3.6E) appeared to be
more disseminated and intense than in the HIV-/HPV16+ tissue (Figure 3.6D). The p16
staining was also observed in HPV negative tissues (Figure 3.6C). In all the tissue
sections examined, p16 staining was both nuclear and cytoplasmic.
Since p16 expression is upregulated during high-risk HPV infections (38, 46, 65), we
sought to determine whether this expression was augmented by the presence of HIV
(Figure 3.6F). For this purpose, we used Image-Pro Premier Offline 9.0 to quantify the
expression of p16 in HIV+/HPV16+ and HIV-/HPV16+ tissues. The expression of p16
signal was normalized to the tissue area and the relative p16 expression levels in the four
groups were compared using Kruskal Wallis test. The medians for the relative p16 signal
across the four groups varied significantly (p<0.05; p=0.0367). Comparison of the
relative p16 signal between the HIV+/HPV16+ and the HIV-/HPV16+ placenta tissues
showed a statistically significant difference (p<0.05; p=0.0142). However, there was no
significant difference in relative p16 signal between the HIV-/HPV16- and the
HIV+/HPV16- placental tissues (p>0.05; p=0.4836).
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Figure 3.6 p16 immunohistochemistry staining. The p16 immunoreactivity was determined in the
sectioned tissues (A) HSD3B1 trophoblast marker (B) Negative control in the absence of primary
antibody. (C) p16 staining in an HIV-/HPV16- tissue. (D) p16 staining in an HIV-/HPV16+ tissue (E)
p16 staining in an HIV+/HPV16+ tissue (F) Quantification of p16 protein in HIV-/HPV16+ and
HIV+/HPV16+ sectioned placental tissues. Image Pro-Premier offline 9.0 was used to determine the
p16 levels in HIV-/HPV16+ and HIV+/HPV16+ sectioned placental tissues. The p16 in levels both
groups were determined in duplicate (Results not shown) and the average p16 values, normalized to
the tissue areas, were compared using Kruskal-Wallis test. The bars represent the median p16 signal.
The median p16 signal varied significantly (p<0.05; p=0.0367) across all the groups. Using the MannWhitney test, we found that there was a significant difference in the p16 signal (p<0.05; p=0.0142)
between the HIV-/HPV16+ and HIV+/HPV16+ groups. We observed an HIV dependent effect on the
expression of p16 in placental trophoblasts.

Detection of HPV16 L1 Protein
The productive infection by human papillomavirus is characterized by the expression of
the late capsid protein (L1) which by itself can assemble into virus like particles (VLPs)
(17, 28). Our PCR results (Figure 3.2) showed that both HIV positive and HIV negative
placental tissues were positive for HPV16 by PCR of the L1 region. We therefore sought
to determine whether L1 protein expression could be detected in placental trophoblasts.
For this purpose we used a Mouse monoclonal anti-HPV16 L1 (H16.V5) antibody (49).
The trophoblast marker slide (Figure 3.7A) served as a reference for the location of the
syncytiotrophoblast cells. To control for background staining due to non-specific binding,
we used normal serum derived IgG4 isotype antibody. As expected, we did not observe
any background staining (Figure 3.7B). Using an HIV-/HPV+ placental tissue, we also
stained for L1 in the absence of the primary antibody and again, observed no detectable
background signal (Figure 3.7B). There was no detectable L1 signal in the HIV-/HPVplacental tissue, (Figure 3.7D).
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The HPV16 L1 protein was detected in HIV+/HPV16+ and HIV-/HPV16+ fetal placental
trophoblasts (Figures 3.7E and F). Both cytotrophoblasts and syncytiotrophoblasts
stained positive for the L1 protein, with most of the staining occurring along columns of
syncytiotrophoblasts which are the terminally differentiated trophoblast cells. The L1
protein expression was also observed in the decidual cells of the maternal side of the
placenta (Results not shown).
It has been postulated that the HIV-1 tat protein can transactivate the Long Control
Region (LCR) of the HPV genome and upregulate the expression of E6 and E7 genes.
Therefore, we chose to assess whether HIV could have an indirect effect on HPV16 L1
expression. We quantified the relative expression of L1 protein presence in placental
tissue samples (Figure 3.7G). To achieve this, we used Image-Pro Premier Offline 9.0
which is software that we trained to discriminate between background signal and the
actual HPV16 L1 signal. Subtraction of background signal gave the relative L1 signal per
tissue area. The HPV16 L1 protein levels in all groups were determined in duplicate and
the average L1 values, normalized to the tissue areas, were compared statistically. The
median HPV16 L1 signal varied significantly (Kruskal Wallis: p<0.05; p=0.0001) across
all the groups. The expression of the L1 protein was significantly different (p<0.05;
p=0.0231) between the HIV-/HPV16+ and HIV+/HPV16+ groups. We concluded that
expression of the L1 protein was clearly influenced by HIV status.

37

38

Figure 3.7 HPV16 L1 immunohistochemistry staining. (A) HSD3B1 trophoblast marker (B) Placental
trophoblasts stained with a Mouse monoclonal anti-IgG isotype control. (C) Placental trophoblasts
stained without a primary antibody. (D)Placental trophoblasts of an HIV-/HPV- tissue stained with
anti-V5L1 antibody. (E) Placental trophoblasts of an HIV+/HPV16+ tissue stained with anti-V5L1
antibody (F) Placental trophoblasts of an HIV-/HPV16+ tissue stained with anti-V5L1 antibody (G)
Quantification of HPV16 L1 protein in HIV-/HPV16+ and HIV+/HPV16+ sectioned placental tissues.
Image Pro-Premier offline 9.0 was used to determine the HPV16 L1 relative levels in HIV-/HPV16+
and HIV+/HPV16+ sectioned placental tissues. The HPV16 L1 protein levels in all groups were
determined in duplicate (Results not shown). The average HPV16 L1 values, normalized to the tissue
areas, were compared using Kruskal-Wallis test. The bars represent the medians of the HPV16 L1
signal. The median HPV16 L1 signal varied significantly (p<0.05; p=0.0001) across all the groups. The
expression of the L1 protein was significantly different (p<0.05; p=0.0231) between the HIV-/HPV16+
and HIV+/HPV16+ groups. We observed an HIV dependent effect on the expression of the L1
protein. As expected, all the HIV-/HPV16- and HIV+/HPV16- samples were negative for HPV16 L1
staining.
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Discussion
Recent studies have demonstrated that HPV can infect epithelial trophoblast cells of the
placenta (76) and HPV DNA has also been detected by PCR in placentas obtained transabdominally from women undergoing amniocentesis (71). These and other studies led us
to explore the prevalence of HPV and the effect of HIV on HPV genotype distribution
within the placental compartment.
To the best of our knowledge, we are the first group to study HPV infection of the
placenta in the context of HIV infection. Using GP5+/6+ PCR as well as CPI/CPII
primers, (Figure 3.2) we were able to detect HPV DNA in both HIV negative and HIV
positive placental tissues.
Married HIV negative women were found to be placenta positive for HPV
[73/81(90.1%)] as were married HIV positive women [75/95(78.9%)] as shown in Table
1. The high incidence of HPV infections among HIV+ and HIV- married women in this
population could be explained in part by multiple sexual partners that they may have had
by the time they were married as most of them are between 15 and 25 years. In low
income countries such as Zambia, young women engage in sex earlier than do women in
more affluent countries. Furthermore, there is a greater rate of women engaging in sex
for monetary benefit, at a young age, which puts them at greater risk of contracting STDs,
such as HPV and HIV. Placental samples were HPV6 positive at high rates, HIV+ (53%)
and HIV- (69%), yet there was no significant difference (p>0.05) between the two groups
(Figure3.4). We did not observe any significant differences between married HIV+ and
HIV- women in most socio demographic status (Years of education and Household size)
as a function of HPV genotype. Nevertheless, we observed a significant difference
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(Fishers’ Exact test: p<0.05; p<0.0001; 2-tailed) in HIV positive women aged 15-25 and
26-36 years [OR 0.0057, 95% CI, 0.000323-0.0992] when age was used as function of
testing positive for HPV. HIV+ women aged 26-36 years were more at risk of testing
positive for HPV than those aged 15-25 years. One plausible explanation for this
observation is that women in this age group are most likely to have had multiple sexual
partners, which put them at risk of being infected with both HIV and HPV.
The observed high HPV prevalence rate (Figure 3.3) in our study was not surprising
because Zambia is endemic for both HIV and HPV (41). HPV prevalence rates as high
as 97.2% have been previously reported among HIV positive Zambian women (51). To
our surprise, we found that the prevalence of HPV in the HIV positive placental tissues
[84/104(80.8%)] was slightly lower than that of the HIV negative ones [86/96(89.6%)],
differing from previous studies (13, 23, 63). However, this difference in HPV prevalence
between the HIV positive and HIV negative placental tissues was not significant (Fisher’s
exact test; p>0.05; p=0.112). Additionally, the prevalence rates for the two groups of
placental tissues were calculated from different total numbers; that is, 86 out of 96 for the
HIV negative group and 84 out of 104 for the HIV positive group.
In assessing the effect of HIV on HPV genotype distribution in the placental
compartment, we found only three different types of HPV, namely the low risk HPV6,
the high risk HPV16 and the rarely isolated HPV90 (Figure 3.4). We discovered that the
incidence of the high-risk HPV16 in HIV positive placental tissues was greater than that
in HIV negative tissues. There was a significant difference (p<0.05; p=0.0241) in the
incidence of HPV16 between the two groups of placental tissues (Figure 3.4). We found
that HIV positive placental tissues were two times more likely to harbor the high-risk
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HPV16 than the HIV negative placental tissues. This result was in agreement with that
obtained in a study conducted by Ng’andwe and colleagues in which they found a ninefold increase in the incidence of the high risk HPV18 in HIV positive versus HIV
negative vaginal lavage samples of Zambian women. It appears that the replication
efficiency of the high risk HPVs is increased in patients whose immune system is
compromised (41).
Interestingly, our placental HPV genotyping distribution differed from the vaginal lavage
results that Ng’andwe et al had previously obtained from the same patients. This
observation suggests that different HPVs could prefer different compartments (Table 3).
In the previous vaginal lavage study by Ng’andwe and colleagues in our laboratory on the
same patient samples (40) HPV16 and HPV18 were recovered in high abundance. This is
in contrast to our present placental study in which HPV6 and 16 were the main genotypes
isolated. Whereas in our study of the vaginal HPV distribution, we recovered 20 different
HPV genotypes, the placental compartment was limited to only 3, suggesting very
selective growth conditions in that tissue. Arguably, HPV6 appears to be the most
successful at exploiting the placental compartment. It is important to acknowledge that
differences in the rate of PCR detection of HPVs in different compartments could
influence these results. The analysis of HPV in the vaginal and placental compartments
was performed under exactly the same conditions using the same protocols. Second
rounds of PCR for samples that tested negative for HPV was used to ensure that we did
not leave out HPV positive samples.
Although HPV90 has been previously reported in an underserved population in United
States, there is dearth of information to determine its prevalence, distribution and disease
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association (44). The presence of HPV90 in cervical lesions as previously reported and
now in placental tissues of our study samples may imply that this genotype has the
potential to replicate in various epithelial compartments. To the best of our knowledge,
we are the first group to report the presence of HPV90 in Zambian specimens and this
finding suggests that unique HPV isolates may be present in this population.
We used p16 as a biomarker for HPV16 infection (38, 46, 65). To study the effect of HIV
on p16 expression in HPV16+ and HPV16- tissues, we performed immunohistochemistry
on tissue sections and stained them with a monoclonal anti-p16 antibody.
Immunohistochemistry results from studies previously conducted on normal cervical
tissues showed absence of p16 expression (65). In contrast, our p16 IHC trophoblastic
results showed moderate expression of p16 both in the HIV-/HPV16- tissue (Figure
3.6C). One plausible explanation for this has been advanced by Tringler et al., 2004, who
have previously demonstrated that p16 is expressed in normal villous cytotrophoblasts
(CTB) between weeks 8 and 10; 15 and 18 as well as 37 and 39 of the gestational period.
In their study, Tringler et al., 2004, observed a high p16 protein expression in the nuclei
of normal CTB and extravillous (ETV) cells at 17 weeks of the gestational period. The
high p16 expression kinetics was in tandem with the reshaping of the villous and was
attributed to death of luminal epithelial cells and the decidua. The net effect of this has
been observed, in a mouse model, to be decidualization of the endometrium and invasion
of trophoblastic cells (65, 75). It is thought that p16 expression occurs in normal villous
CTB in order to suppress villous proliferation and consequently promote the invasion
process (65). Overall, the relative p16 expression median across all the 4 groups varied
significantly (Kruskal-Wallis: p<0.05; p=0.0367) as shown in Figure 3.6F. We observed
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a small difference in p16 expression between the HIV-/HPV16- and HIV+/HPV16tissues , however, it was not significant (Mann-Whitney: p>0.05; p=0.4836; Figure 3.6F).
This result suggests that HIV may have a mild effect on the expression of p16 in HPVtissues. On the other hand, we observed a significant difference (Mann-Whitney: p<0.05;
p=0.0142) in relative p16 expression between the HIV+/HPV16+ and HIV-/HPV16+
tissues (Figure 3.6F). This HIV-dependent effect on p16 expression could be attributed to
a number of different indirect effects: that HIV can attenuate the cellular mediated
immune responses (42) and also that the HIV-1 tat protein transactivates the HPV Long
Control Region (LCR) causing an upregulation in the expression of the HPV18 E7
oncogene (64). The elevated E7 oncoprotein in turn binds to the E2F-pRb complex,
causing the release of E2F and binds to pRb, which leads to induction of overexpression
of p16 (38, 46, 65). Thus, the HIV-1 tat protein may influence HPV infection and
increase p16 protein expression in trophoblastic cells. To determine whether this is
possible in vivo, there is need to perform dual staining for HIV-1 tat and the HPV16
LCR.
In vitro studies have shown that the human papillomavirus can replicate productively in
placental trophoblasts. In our study, we performed immunohistochemistry staining for the
HPV16 L1 protein (Figure 3.7) using a monoclonal anti-HPV16 V5 L1 antibody (67) on
patient-derived placental samples. The L1 protein is the major viral capsid protein that is
expressed during the late phase of the HPV life cycle and can by itself spontaneously
assemble into virus like particles (17, 28). Neither the HIV-/HPV- negative control
(Figure 3.7D) nor did the anti-IgG4 isotype control (Figure 3.7B) give a positive signal
for HPV16 L1. Additionally, the HIV+/HPV16+ tissue section stained without anti-L1
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(Figure 3.7C) gave no detectable signal for HPV16 L1. We observed positive staining for
L1 protein expression in HIV+/HPV16+ (Figure 3.7E) and HIV-/HPV16+ (Figure 3.7F)
placental trophoblasts. The staining was observed both in cytotrophoblast and
syncytiotrophoblast cells. It appears that HPV16 establishes its productive infection in
these cells. To further elucidate this assertion, we wanted to perform electron Microscopy
on the placental samples so that we could show the presence of HPV16 virion particles in
these cells. This was however not possible because the membranes were disrupted during
paraffin embedding of the placental tissues. Therefore as an alternative to this method,
we intend to show evidence of the HPV16E1^E4 splicing product in trophoblastic cells in
our follow up study. Having identified the cells that were positive for HPV16 L1
staining, we quantified the relative HPV16 L1 protein using Pro-Premier Offline 9.0. We
observed that the relative HPV16 L1 median signal varied significantly (Kruskal-Wallis:
p<0.05; p=0.0001) across all the 4 groups (Figure 3.7G). The elevated expression of
HPV16+ L1 in HIV+/HPV16+ trophoblastic cells in comparison to the HIV-/HPV16+
suggests that HIV has an effect on HPV16 L1 protein expression. To further explore this,
we compared the HPV16 L1 relative signal between the HIV+/HPV16+ and HIV/HPV16+ tissue samples (Figure 3.7G) and observed that there was a significant
difference (Mann-Whitney: p<0.05; p=0.0231). The HIV dependent effect on HPV16 L1
expression in placental trophoblasts could be attributed to the ability of HIV-1 tat to
transactivate the HPV LCR as alluded to earlier in the case of p16 expression (13, 64).
Thus, our HP16 L1 immunohistochemistry result corroborates the in vitro report that
HPV can replicate productively in 3A trophoblasts in tissue culture (79).
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Infection of the cervix with the HR-HPVs such as HPV16 and 18 are associated with
cervical dysplasia (16, 83). Interestingly, we did not find obvious pathology in placental
trophoblasts related to the presence of HR-HPV16. One plausible explanation for the
absence of pathology in trophoblastic cells is that extravillous trophoblast cells express
neither Major Histocompatibility Complex (MHC) class I nor class II molecules (22, 45).
The lack of MHC classes I and II expression implies that the HPV virus can freely
replicate without inducing an immune response.
Finally, in this study, we have shown the presence of HPV in placental trophoblasts using
both polymerase chain reaction and HPV16 L1 immunohistochemistry methods. We have
also shown, for the first time, the effect of HIV on HPV infection in placental
trophoblasts.
In our follow up studies, we are determining the presence of HPV DNA in placental
trophoblasts by in situ hybridization. Further corroboration of HPV infection of placental
trophoblastic cells is being done by reverse transcription PCR for the E1^E4 spliced
product, which is the most highly expressed protein in productive infection by the human
papillomaviruses. Additionally, we intend to perform HIV-1 p24 IHC using a polyclonal
rabbit anti-p24 with a view to determining whether HIV is present in the placental cells.
We further want to perform p24 staining using a monoclonal antibody in order to
corroborate our results. This will be followed by dual-staining for HIV-1 p24 vs the cell
markers, HIV-1 p24 vs HPV16 L1 and HIV-1 p24 vs HPVE1^E4. This will help us
determine which cells are infected by HIV and HPV.
Finally, our main focus for this study was to determine the effect of HIV on high risk
HPV16 infection of placental trophoblasts. We therefore now intend to perform

46

immunohistochemistry analysis for the low risk HPV6 and compare the results with those
of HPV16 IHC. Overall, our results support the conclusion that a subset of HPVs infects
the placenta and their prevalence is influenced by HIV status.
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